Engage has promising data. Now it needs money
Engage Therapeutics, a scrappily funded startup focused on epilepsy, has demonstrated that a once-failed drug can treat seizures. Now it needs to replicate the results in larger studies, which will mean once more convincing investors to back a family affair.
As STAT’s Kate Sheridan reports, Engage’s drug, a rescue inhaler loaded with a modified form of Xanax, charted a promising response rate in a study enrolling 76 patients with epilepsy. But that study looked only at hospitalized patients, and convincing the FDA will likely require trials in other settings. Funding the first study was not exactly easy, but Greg Mayes, who founded Engage after his son was diagnosed with epilepsy in 2014, believes the data make his company’s case more compelling.
“I’m going to be able to circle back to people who passed on the Series A and say, ‘Hey, look, here’s the good news,’” Mayes said. “I’m so excited to be able to do that.”
Read more.
As STAT’s Kate Sheridan reports, Engage’s drug, a rescue inhaler loaded with a modified form of Xanax, charted a promising response rate in a study enrolling 76 patients with epilepsy. But that study looked only at hospitalized patients, and convincing the FDA will likely require trials in other settings. Funding the first study was not exactly easy, but Greg Mayes, who founded Engage after his son was diagnosed with epilepsy in 2014, believes the data make his company’s case more compelling.
“I’m going to be able to circle back to people who passed on the Series A and say, ‘Hey, look, here’s the good news,’” Mayes said. “I’m so excited to be able to do that.”
Read more.
.png)
No hay comentarios:
Publicar un comentario